Free Trial
NASDAQ:EDIT

Editas Medicine Q3 2024 Earnings Report

Editas Medicine logo
$2.54 +0.10 (+3.89%)
As of 11:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Editas Medicine EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.75
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.55

Editas Medicine Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
$3.93 million
Beat/Miss
Missed by -$3.87 million
YoY Revenue Growth
-98.90%

Editas Medicine Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Monday, November 4, 2024
Conference Call Time
7:30AM ET

Upcoming Earnings

Editas Medicine's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025

Editas Medicine Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
Editas Medicine Inc EDIT Company Vitals - U.S. News
See More Editas Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email.

About Editas Medicine

Editas Medicine (NASDAQ:EDIT), a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

View Editas Medicine Profile

More Earnings Resources from MarketBeat